Pyrazinamide Resistance, Mycobacterium tuberculosis Lineage and Treatment Outcomes in San Francisco, California

BACKGROUND: Pyrazinamide (PZA) is a first line agent for the treatment of active tuberculosis. PZA is also considered a potent companion drug for newer regimens under development. There are limited data on the demographic, clinical, and pathogen characteristics of PZA resistant tuberculosis. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Budzik, Jonathan M., Jarlsberg, Leah G., Higashi, Julie, Grinsdale, Jennifer, Hopewell, Phil C., Kato-Maeda, Midori, Nahid, Payam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997554/
https://www.ncbi.nlm.nih.gov/pubmed/24759760
http://dx.doi.org/10.1371/journal.pone.0095645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997554/
https://www.ncbi.nlm.nih.gov/pubmed/24759760
http://dx.doi.org/10.1371/journal.pone.0095645

Ejemplares similares